Health
Emergent Leads Mpox-Tied Stock Gains as Investors Await Approval
- Shotmaker seeks approval to use its smallpox vaccine for mpox
- Other health stocks up after WHO declared emergency this week
This article is for subscribers only.
Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus.
The vaccine maker — which has said it expects US Food and Drug Administration approval by the end of this quarter — climbed more than 60% over the past four sessions with the World Health Organization declaring the mpox outbreak in Africa a global health emergency on Wednesday. The stock has seen its value more than quadruple in 2024.